Literature DB >> 27638892

Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.

Maurie Markman1.   

Abstract

A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.
© The Author(s) 2016.

Entities:  

Keywords:  cervical cancer; chemotherapy of gynecologic cancers; cisplatin; endometrial cancer; gynecologic cancers; ovarian cancer; randomized trials

Mesh：

Substances：

Year:  2016        PMID： 27638892      PMCID： PMC5373277          DOI： 10.1177/1745505716655555

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN： 1745-5057


  15 in total

Review 1.  Chemotherapy for advanced, recurrent, and metastatic cervical cancer.

Authors:  David H Moore
Journal:  J Natl Compr Canc Netw       Date:  2008-01       Impact factor: 11.908

Review 2.  Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

Authors:  Gini F Fleming
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

3.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

4.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer.

Authors:  Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Megan Petersen; Gary S Leiserowitz
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

6.  Ovarian cancer.

Authors:  Bryan T Hennessy; Robert L Coleman; Maurie Markman
Journal:  Lancet       Date:  2009-09-28       Impact factor: 79.321

7.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

8.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

9.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

Review 10.  Medical therapy of endometrial cancer: current status and promising novel treatments.

Authors:  Emily K Hill; Don S Dizon
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.